Bulletin, Institute

Fall 2017 FAST Closing Showcase Celebrates Eight Companies

Cairn Biosciences Founder & CEO, Mary Ludlam, offers inspirational FAST Retrospective

CLSI celebrated key milestones at the Fall 2017 FAST Closing Showcase at Byers Auditorium in UCSF San Francisco on December 13, 2017. The Showcase marked the culmination of the Fall program and included presentations from eight graduating FAST companies: BioAmp Diagnostics, developing diagnostic assays that can detect antibiotics resistance directly in patient samples; Phi Therapeutics, developing a platform technology to enhance natural phage with payloads to improve bacterial targeting and neutralization; Pheronym, an Ag-biotech company developing green solutions for agricultural pest control; Oomni, developing drugs that simultaneously target two pathways of importance for inhibiting cancer growth and metastasis; Inflammatix, developing diagnostic tests based on ‘reading’ the immune system; DeviceFarm, developing a gas-based treatment to treat nail fungal infections; Siolta, developing microbial-based therapeutics for the prevention and treatment of inflammatory diseases, such as asthma; and STATegics, developing breakthrough new treatments for life-threatening rare neurodegenerative diseases.

The program also opened up with a retrospective from previous FAST graduate, Mary Ludlam, CEO of Cairn Biosciences, who discussed how the FAST program helped further their companies’ success,  and closed off with the announcement of the PharmaDirections JumpStart Award given to Jeff Spencer of STATegics.

SPRING 2018 FAST Applications Open

Applications for the Spring 2018 program are open through January 26, 2018.  Apply now. For information on the FAST program, contact Steve Karp at or Julie Harness at